New England Journal of Medicine· 2015Q1

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

Jordan J. Feld, Ira M. Jacobson, Christophe Hézode, Tarik Asselah et al.

1,117citations
Q1SCImago
2015year

Short summary

A 12-week, once-daily regimen of sofosbuvir-velpatasvir achieved a 99% sustained virologic response rate in patients with chronic Hepatitis C virus (HCV) genotypes 1, 2, 4, 5, or 6, including those with compensated cirrhosis.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hepatology

HepatologyMedicine